Iron-based phosphate binders – a new element in management of hyperphosphatemia

Abstract

Introduction: Management of serum phosphorus in patients with chronic kidney disease remains a significant clinical challenge. A pivotal component of the clinical approach to maintaining serum phosphorus concentrations towards the normal range is the use of phosphate binding agents in addition to comprehensive dietary counseling. The available agents work similarly by capitalizing on a cation within the agent to bind negatively charged phosphorus, forming an insoluble complex and reducing ingested phosphorus absorption. Despite several effective options for phosphate binder therapies, patient adherence remains an issue, mainly due to adverse effect profiles and large daily pill burdens.

Areas covered: Two new iron-based phosphate binder therapies have recently become available in the United States, sucroferric oxyhydroxide and ferric citrate. These agents have both been shown to effectively reduce serum phosphorus comparably to widely used calcium-based binders and sevelamer salts.

Expert opinion: The two new iron-based binders differ substantially with regard to phosphate binding chemistry and iron absorption profiles. Their place in therapy is still evolving and the impact of pill burden, gastrointestinal adverse effect profiles, potential cost reduction of anemia therapies and physiologic effects of long-term iron exposure need to be further evaluated.

Keywords:

• ferric citrate
• hyperphosphatemia
• phosphate binders
• sucroferric hydroxyoxide

View correction statement:

Corrigendum

Article highlights.

• Treatment of hyperphosphatemia in chronic kidney diseases is challenging and is limited by adherence and tolerance profiles.

• Two new iron-based phosphate binders (sucroferric oxyhydroxide and ferric citrate coordination complex) have been recently approved by the Food and Drug Administration.

• Both iron-based binders demonstrate efficacy in reduction of serum phosphorus.

• Sucroferric oxyhydroxide and ferric citrate coordination complex are different with regard to phosphate binding chemistry, iron absorption profiles and adverse effects.

• The place in therapy for both agents is evolving.

This box summarizes key points contained in the article.